The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.

导出原文传递

翻译打印收藏纠错

作者： Hanifi-Moghaddam P ^[1] ; Sijmons B ; Ott MC ; van-Ijcken WF ; Nowzari D ; Kuhne EC ; van-der-Spek P ; Kloosterboer HJ ; Burger CW ; Blok LJ

作者单位： Department of Reproduction and Development, Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands. p.hanifi_moghaddam@erasmusmc.nl ^[1]

关键词 Endometrial Neoplasms Estrogens Gene Expression Regulation Neoplastic 子宫内膜肿瘤雌激素类基因表达调控肿瘤激素替代疗法甲羟孕酮17-乙酸酯

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Journal of Molecular Endocrinology

2006年37卷3期

405-413页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.

Journal of Molecular Endocrinology

相似文献

Journal of Molecular Endocrinology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line.

Journal of Molecular Endocrinology

相似文献

Journal of Molecular Endocrinology

相关期刊

检索历史清除